Healthcare / BiotechnologyNYSE American
$1.37
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-23.7M · quality 44.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
0/100
F
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$342M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-142.6%
↓Gross Margin
N/A
•Debt/Equity
N/A
•Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2009–2025 · 16 años de histórico normalizado
Revenue CAGR
+13.5%
FCF CAGR
—
FCF margin
-133.6%
FCF / Net income
0.31x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $14.6M · net income $-63.5M · FCF $-19.4M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||||||||||
| Revenue | $14.6M | $14.6M | $9.5M | $8.9M | $14.7M | $4.3M | $1.8M | $3.5M | $5.0M | $3.5M | $5.9M | $7.0M | $5.2M | $4.4M | $3.9M | $4.4M | $3.7M | $1.9M |
| Net Income | $-63.5M | $-63.5M | $-18.6M | $-21.5M | $-26.3M | $-43.0M | $-20.6M | $-11.7M | $-46.0M | $-20.0M | $33.6M | $-47.0M | $-36.4M | $-43.9M | $-21.4M | $-16.5M | $-11.2M | $-5.1M |
| EBITDA | $-35.9M | $-35.9M | $-20.9M | $-24.2M | $-21.9M | $-48.5M | $-25.6M | $-37.9M | $-40.7M | $-38.0M | $-57.8M | $-64.7M | $-49.6M | — | — | — | — | — |
| EPS | -0.28 | -0.28 | -0.09 | -0.12 | -0.15 | -0.26 | — | — | — | -0.17 | 0.34 | -0.59 | -0.55 | — | — | — | — | — |
| Gross Margin | — | — | — | 92.5% | 95.0% | 67.2% | 78.9% | 88.3% | 93.9% | 95.1% | 94.0% | 84.3% | 84.0% | 82.1% | 88.9% | 98.2% | 99.3% | — |
| Operating Margin | -251.6% | -251.6% | -226.1% | -276.5% | -153.2% | -1133.6% | -1448.4% | -1106.0% | -837.9% | -1125.0% | -995.6% | -935.3% | -966.5% | -1262.7% | -638.5% | -421.4% | -265.7% | -182.9% |
| Net Margin | -436.5% | -436.5% | -195.9% | -240.2% | -178.7% | -991.0% | -1130.8% | -333.1% | -922.0% | -577.7% | 566.8% | -667.9% | -694.4% | -989.7% | -547.2% | -372.5% | -301.6% | -267.2% |
| Cash Flow | ||||||||||||||||||
| Free Cash Flow | $-19.4M | $-19.4M | $-23.7M | $-29.2M | $646000.00 | $-23.9M | $-19.8M | $-32.4M | $-31.4M | $-31.8M | $-44.6M | $-45.8M | — | $-31.8M | $-20.1M | $-14.6M | $-8.0M | $-4.3M |
| Returns | ||||||||||||||||||
| ROE | -142.6% | -142.6% | -23.7% | -33.9% | -35.8% | -46.6% | -21.5% | -10.4% | -49.0% | -12.3% | 28.5% | -182.0% | -99.9% | -296.5% | -223.5% | -57.7% | -29.3% | — |
| Growth & Yield | ||||||||||||||||||
| Revenue Growth | 53.2% | 53.2% | 6.2% | -39.2% | 238.7% | 137.7% | -48.1% | -29.5% | 44.2% | -41.6% | -15.8% | 34.2% | 18.3% | 13.2% | -11.7% | 19.6% | 92.6% | — |
| EPS Growth | -211.1% | -211.1% | 25.0% | 20.0% | 42.3% | — | — | — | — | -150.0% | 157.6% | -7.3% | — | — | — | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Unavailable: positive start/end prices are required.